구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Relmacabtagene Autoleucel (Autoleucel, Autoleucel (Relmacabtagene Autoleucel)) Sun Yat-sen University·Large B Cell Diffuse Lymphoma 47 trials |
|---|---|
Overview Program | Autoleucel (Relmacabtagene Autoleucel) |
Overview Company | Sun Yat-sen University |
Overview Modality | CGT |
Overview Target | Large B Cell Diffuse Lymphoma |
Overview Indication | Large B Cell Diffuse Lymphoma; Mantle Cell Lymphoma (MCL) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targeted chimeric antigen receptor |
MoA Biomarker | biomarkers of CAR-T cell expansion, we analyzed absolute lymphocyte count (ALC) as a surrogate biomarker in a |
PK/PD Species | Human |
PK/PD Animal (cat.) | Human |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Human |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | Epitope mapping of humoral immunogenicity of orvacabtagene autoleucel shows an IgM response with minimal impact on CAR T cellular kinetics.. Orvacabtagene autoleucel (orva-cel) is a fully human B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cell therapy evaluated in a phase 1/2 study in patients with relapsed or refractory multiple myeloma (RRMM). To assess treatment-r… |
Toxicology CRS | 4% |
Clinical Safety signal | Epitope mapping of humoral immunogenicity of orvacabtagene autoleucel shows an IgM response with minimal impact on CAR T cellular kinetics.. Orvacabtagene autoleucel (orva-cel) is a fully human B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cell therapy evaluated in a phase 1/2 study in patients with relapsed or refractory multiple myeloma (RRMM). To assess treatment-r… |
Clinical Selected reported efficacy | ORR 38% |
Clinical Reported ORR | 38.0% |
Clinical Reported PFS | 3.5 |
Clinical Reported OS | 9.6 |
Clinical Result source | ClinicalTrials.gov NCT05537766 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT05537766 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Relmacabtagene Autoleucel (Autoleucel, Autoleucel (Relmacabtagene Autoleucel)) Sun Yat-sen University·Large B Cell Diffuse Lymphoma 47 trials |
|---|---|
Overview Program | Autoleucel (Relmacabtagene Autoleucel) |
Overview Company | Sun Yat-sen University |
Overview Modality | CGT |
Overview Target | Large B Cell Diffuse Lymphoma |
Overview Indication | Large B Cell Diffuse Lymphoma; Mantle Cell Lymphoma (MCL) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targeted chimeric antigen receptor |
MoA Biomarker | biomarkers of CAR-T cell expansion, we analyzed absolute lymphocyte count (ALC) as a surrogate biomarker in a |
PK/PD Species | Human |
PK/PD Animal (cat.) | Human |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Human |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | Epitope mapping of humoral immunogenicity of orvacabtagene autoleucel shows an IgM response with minimal impact on CAR T cellular kinetics.. Orvacabtagene autoleucel (orva-cel) is a fully human B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cell therapy evaluated in a phase 1/2 study in patients with relapsed or refractory multiple myeloma (RRMM). To assess treatment-r… |
Toxicology CRS | 4% |
Clinical Safety signal | Epitope mapping of humoral immunogenicity of orvacabtagene autoleucel shows an IgM response with minimal impact on CAR T cellular kinetics.. Orvacabtagene autoleucel (orva-cel) is a fully human B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cell therapy evaluated in a phase 1/2 study in patients with relapsed or refractory multiple myeloma (RRMM). To assess treatment-r… |
Clinical Selected reported efficacy | ORR 38% |
Clinical Reported ORR | 38.0% |
Clinical Reported PFS | 3.5 |
Clinical Reported OS | 9.6 |
Clinical Result source | ClinicalTrials.gov NCT05537766 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT05537766 |
추천 비교
추천 비교